This Study is designed to determine whether treatment of CFRD with glargine insulin will
improve hemoglobin A1c, weight and muscle mass compared to the traditional regimen of bedtime
NPH insulin.
Phase:
Phase 3
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute